David Tuveson
#84,871
Most Influential Person Now
American cancer biologist
David Tuveson's AcademicInfluence.com Rankings
David Tuvesonbiology Degrees
Biology
#4477
World Rank
#6672
Historical Rank
Molecular Biology
#817
World Rank
#837
Historical Rank
David Tuvesonphilosophy Degrees
Philosophy
#5425
World Rank
#8219
Historical Rank
Logic
#2711
World Rank
#3741
Historical Rank
Download Badge
Biology Philosophy
David Tuveson's Degrees
- Doctorate Medicine University of Pennsylvania
- PhD Molecular Biology University of Pennsylvania
Why Is David Tuveson Influential?
(Suggest an Edit or Addition)According to Wikipedia, David Arthur Tuveson is an American cancer biologist and is currently Roy J. Zuckerberg Professor of Cancer Research as well as The Cancer Center Director at Cold Spring Harbor Laboratory. Dr. Tuveson is also the Chief Scientist for the Lustgarten Foundation for Pancreatic Cancer Research. He is known for developing some of the first mouse models of pancreatic cancer and more recently, for his work developing pancreatic cancer organoids.
David Tuveson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) (4091)
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer (2009) (2855)
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. (2003) (2209)
- Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. (2001) (2059)
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. (2005) (2050)
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis (2011) (1806)
- Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. (2001) (1795)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) (1752)
- Restoration of p53 function leads to tumour regression in vivo (2007) (1737)
- Organoid Models of Human and Mouse Ductal Pancreatic Cancer (2015) (1403)
- A framework for advancing our understanding of cancer-associated fibroblasts (2020) (1376)
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer (2013) (1321)
- Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer (2017) (1240)
- Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome (2004) (1220)
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma (2010) (1176)
- Somatic activation of the K-ras oncogene causes early onset lung cancer in mice (2001) (1151)
- The Pancreas Cancer Microenvironment (2012) (1044)
- Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. (2003) (994)
- KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. (2001) (988)
- Transcriptional Regulation by Nrf2 (2017) (922)
- ATP citrate lyase inhibition can suppress tumor cell growth. (2005) (901)
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α (2010) (862)
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer (2012) (839)
- Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. (2004) (807)
- Pancreatic cancer (1988) (797)
- Dynamics of the immune reaction to pancreatic cancer from inception to invasion. (2007) (791)
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy (2014) (776)
- Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. (2019) (709)
- Stromal biology and therapy in pancreatic cancer (2010) (696)
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications (2001) (696)
- Maximizing mouse cancer models (2007) (677)
- Fibroblast heterogeneity in the cancer wound (2014) (656)
- IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. (2018) (549)
- Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. (2018) (538)
- In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma (2011) (525)
- The differential effects of mutant p53 alleles on advanced murine lung cancer. (2005) (496)
- Cancer modeling meets human organoid technology (2019) (427)
- Stromal biology and therapy in pancreatic cancer: a changing paradigm (2015) (418)
- Suppression of BRAF(V599E) in human melanoma abrogates transformation. (2003) (417)
- Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. (2006) (385)
- nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. (2012) (352)
- Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. (2007) (347)
- CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. (1993) (344)
- The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1 (2015) (333)
- Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. (2005) (331)
- Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19 (1991) (324)
- Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. (2004) (321)
- Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. (2011) (312)
- Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis (2016) (299)
- Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis (2017) (298)
- ROS in Cancer: The Burning Question. (2017) (295)
- DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. (2020) (291)
- The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma (2012) (287)
- Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. (2004) (283)
- Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia (2013) (272)
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution (2020) (258)
- NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer (2016) (256)
- Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. (2006) (248)
- The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics (2006) (245)
- Stromal biology and therapy in pancreatic cancer: ready for clinical translation? (2018) (217)
- Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. (2011) (216)
- Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study (2020) (212)
- Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. (2018) (209)
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer (2013) (208)
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity (2020) (187)
- Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches (2012) (178)
- Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells (2019) (178)
- Requirement for Rac1 in a K-ras induced lung cancer in the mouse. (2007) (175)
- SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. (2011) (175)
- Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. (2019) (173)
- Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. (2016) (171)
- Modeling pancreatic cancer with organoids. (2016) (166)
- The promise and perils of antioxidants for cancer patients. (2014) (166)
- Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. (2010) (157)
- BRAF as a potential therapeutic target in melanoma and other malignancies. (2003) (153)
- What we have learned about pancreatic cancer from mouse models. (2012) (152)
- In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma (2011) (151)
- A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. (1993) (150)
- A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel (2008) (145)
- SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice (2013) (141)
- Modeling human lung cancer in mice: similarities and shortcomings (1999) (138)
- Roadmap for the Emerging Field of Cancer Neuroscience (2020) (136)
- The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice (2019) (132)
- TLR9 ligation in pancreatic stellate cells promotes tumorigenesis (2015) (131)
- Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. (2006) (130)
- Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. (2007) (129)
- C-Raf is required for the initiation of lung cancer by K-Ras(G12D). (2011) (122)
- BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model (2015) (121)
- The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. (2007) (120)
- The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. (1991) (120)
- Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer (2020) (119)
- TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma (2018) (116)
- Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. (2004) (111)
- Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization (2017) (111)
- Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series (2020) (109)
- Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. (2017) (109)
- Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma (2012) (102)
- Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex (1991) (99)
- Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer (2021) (98)
- Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. (2014) (96)
- Predictive in vivo animal models and translation to clinical trials. (2012) (95)
- Accumulation of Extracellular Hyaluronan by Hyaluronan Synthase 3 Promotes Tumor Growth and Modulates the Pancreatic Cancer Microenvironment (2014) (95)
- Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening (2018) (93)
- Ras redux: rethinking how and where Ras acts. (2003) (92)
- Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer. (2019) (90)
- Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis (2004) (89)
- Ductal pancreatic cancer in humans and mice. (2005) (88)
- Patient‐derived organoid models help define personalized management of gastrointestinal cancer (2018) (86)
- Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer (2012) (85)
- Translational medicine: Cancer lessons from mice to humans (2011) (84)
- Technologically advanced cancer modeling in mice. (2002) (84)
- ADAM8 as a drug target in Pancreatic Cancer (2015) (84)
- Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma (2013) (76)
- Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. (2005) (74)
- BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages (2015) (74)
- Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions (2012) (73)
- Preclinical models of pancreatic ductal adenocarcinoma (2015) (69)
- Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism (2019) (69)
- MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model (2015) (69)
- Modelling oncogenic Ras/Raf signalling in the mouse. (2009) (68)
- Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. (2020) (67)
- Cancer Cell–Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma (2020) (66)
- RAS in cellular transformation and senescence. (2009) (66)
- Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice (2011) (66)
- Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus (2015) (66)
- A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (2018) (63)
- C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). (2009) (61)
- Model organoids provide new research opportunities for ductal pancreatic cancer (2016) (60)
- IL-1-induced JAK/STAT signaling is antagonized by TGF- β to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. (2019) (58)
- Pancreatic cancer in mice and man: the Penn Workshop 2004. (2006) (54)
- The deubiquitinase USP 9 X suppresses pancreatic ductal adenocarcinoma (2012) (53)
- A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy (2011) (53)
- p53 mutations change phosphatidylinositol acyl chain composition. (2015) (53)
- Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells (2019) (52)
- Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. (2018) (52)
- Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma (2017) (51)
- Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. (2012) (50)
- Organoid models for translational pancreatic cancer research. (2019) (47)
- The use of GEM models for experimental cancer therapeutics (2008) (46)
- Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. (2006) (45)
- Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation (2019) (45)
- SOAT1 promotes mevalonate pathway dependency in pancreatic cancer (2020) (44)
- Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer (2017) (41)
- Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade (2021) (39)
- Organoid Models for Cancer Research (2019) (39)
- PanIN neuroendocrine cells promote tumorigenesis via neuronal crosstalk. (2017) (38)
- Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer (2019) (35)
- Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer (2020) (35)
- Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer (2013) (35)
- Signal transduction pathways in sarcoma as targets for therapeutic intervention (2001) (34)
- Metabolic Rewiring by Loss of Sirt5 Promotes Kras-induced Pancreatic Cancer Progression. (2021) (32)
- Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death (2019) (32)
- Deploying Mouse Models of Pancreatic Cancer for Chemoprevention Studies (2010) (31)
- SIRT1–NOX4 signaling axis regulates cancer cachexia (2020) (31)
- K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. (2008) (30)
- PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk. (2017) (29)
- Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. (2007) (28)
- nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer (2014) (26)
- Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma (2015) (26)
- Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. (2014) (26)
- Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma (2020) (25)
- Targeting oncogene dependence and resistance. (2003) (24)
- Physiological analysis of oncogenic K-ras. (2006) (23)
- VAV1: A new target in pancreatic cancer? (2005) (22)
- Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort Study (2020) (21)
- Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma (2020) (21)
- Deciphering cancer fibroblasts (2018) (21)
- Dynamic changes during the treatment of pancreatic cancer (2018) (21)
- Perspectives on the role of Wnt biology in cancer (2019) (20)
- Mist 1-KrasG 12 D KnockIn Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma (2005) (20)
- Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo (2014) (20)
- RhoC Interacts with Integrin α5β1 and Enhances Its Trafficking in Migrating Pancreatic Carcinoma Cells (2013) (20)
- Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. (2018) (20)
- Deconstructing tumor heterogeneity: the stromal perspective (2020) (18)
- Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. (2006) (17)
- Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic (2016) (17)
- Untangling the genetics from the epigenetics in pancreatic cancer metastasis (2017) (15)
- In Search of an Early Warning System for Pancreatic Cancer (2003) (14)
- Single-Pass vs 2-Pass Endoscopic Ultrasound-guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. (2020) (14)
- Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer (2019) (14)
- A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of renal tubules (2015) (13)
- 5th International Symposium on Focused Ultrasound (2016) (13)
- ADAM 8 as a drug target in pancreatic cancer (2015) (13)
- Suppression of BRAFV 599 E in Human Melanoma Abrogates Transformation 1 (2003) (12)
- Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer (2022) (11)
- Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers (2020) (11)
- Mouse Models of Pancreatic Ductal Adenocarcinoma. (2015) (11)
- Pancreatic Ductal Adenocarcinoma Comprises Coexisting Regulatory States with both Common and Distinct Dependencies (2020) (11)
- Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial (2022) (11)
- TP 63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma Graphical (2018) (11)
- Securing the future of the clinician-scientist (2020) (11)
- Challenges and Opportunities in Modeling Pancreatic Cancer. (2016) (10)
- Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA (2020) (10)
- Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis (2016) (10)
- Impact of COVID-19 Pandemic on Cancer Research (2020) (9)
- Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells (2016) (9)
- A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC). (2014) (9)
- Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma (2020) (9)
- Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer (2021) (8)
- Lead Identification using 3D Models of Pancreatic Cancer: Development of 3D Tumor Models for High-throughput Screening. (2022) (8)
- Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) (2004) (8)
- BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling (2022) (8)
- Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy (2022) (7)
- Precision medicine in pancreatic cancer: Patient derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. (2022) (7)
- Olive , Cancer of Chemotherapy in a Mouse Model of Pancreatic Inhibition of Hedgehog Signaling Enhances Delivery (2009) (7)
- MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. (2014) (7)
- KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice (2020) (7)
- An shRNA silencing a non‐toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell (2009) (7)
- Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics (2021) (7)
- Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution (2020) (6)
- Recapitulating human cancer in a mouse (2013) (6)
- Soils and Seeds That Initiate Pancreatic Cancer Metastasis. (2017) (6)
- A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth. (2019) (6)
- Pancreatic cancer foiled by a switch of tumour subtype (2018) (6)
- Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers? (2015) (5)
- Abstract C57: Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (2019) (5)
- Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma. (2018) (5)
- Phase I trial of imatinib and temozolomide in patients with metastatic melanoma. (2004) (5)
- Detecting and diagnosing ampullary neoplasms (2004) (5)
- Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. (2020) (4)
- M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer. (2012) (4)
- A rapid and tunable method to temporally control Cas9 expression enables the identification of essential genes and the interrogation of functional gene interactions in vitro and in vivo (2015) (4)
- Murine Lung Cancer Alleles on Advanced p 53 The Differential Effects of Mutant Updated (2005) (4)
- The RAS and YAP1 dance, who is leading? (2014) (4)
- 738PStrong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) (2017) (3)
- SPDEF promotes the classical subtype of pancreatic ductal adenocarcinoma (2022) (3)
- A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (2018) (3)
- Augmenting NF-kappaB in poor-risk CLL : A general paradigm for other cancers ? (2018) (3)
- Inhibition of BRAF activity by the Raf kinase inhibitor BAY 43-9006 inhibits melanoma tumor development (2004) (2)
- Abstract 4844: Extracellular hyaluronan accumulation by hyaluronan synthase 3 promotes pancreatic cancer growth and modulates tumor microenvironment via epithelial-mesenchymal transition (2014) (2)
- A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC). (2017) (2)
- Cancer: Double trouble for tumours (2017) (2)
- Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer (2020) (2)
- Tumor and Stem Cell Biology Impaired JNK Signaling Cooperates with KrasG 12 D Expression to Accelerate Pancreatic Ductal Adenocarcinoma (2014) (2)
- ROS in translation: Chink in the armor (2017) (2)
- Genetic Ancestry Inference from Cancer-Derived Molecular Data across Genomic and Transcriptomic Platforms (2022) (2)
- Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma (2013) (2)
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity (2020) (2)
- Abstract PR03: NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer (2017) (2)
- Expression of oncogenic Kras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways (2007) (2)
- Detection of Chemotherapy-Resistant Pancreatic Cancer Using a Glycan Biomarker (2020) (2)
- Quid pro Quo: A Tumor is Not Alone. (2017) (1)
- A TEAD2-driven endothelial-like program shapes basal-like differentiation and metastasis of pancreatic cancer. (2023) (1)
- Longitudinal Intravital Imaging Through Clear Silicone Windows. (2022) (1)
- Abstract A64: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. (2012) (1)
- Kras in Organoids. (2018) (1)
- Abstract 1563: Spatial transcriptomics reveals heterogeneity and pathway dependencies of cancer associated fibroblasts in pancreatic ductal adenocarcinoma (2022) (1)
- Abstract A27: Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma (2016) (1)
- BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking CLU+ CAF expression with HSF1 signaling (2021) (1)
- Abstract 3647: Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer (2022) (1)
- Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy for personalized cancer treatment (2018) (1)
- 1 Nix-mediated mitophagy promotes pancreatic cancer (2019) (1)
- Abstract B16: Using human patient-derived organoids to identify genetic dependencies in pancreatic cancer (2016) (1)
- A framework for advancing our understanding of cancer-associated fibroblasts (2020) (1)
- Finding and killing the CRABs of pancreatic cancer. (2009) (1)
- Pancreatic stellate cell heterogeneity in cancer (2016) (1)
- Fighting the Sixth Decade of the Cancer War with Better Cancer Models. (2021) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine (2017) (1)
- A path to translation: How 3D patient tumor avatars enable next generation precision oncology. (2022) (1)
- Abstract 302: Characterization of effects of M402 on EMT in pancreatic ductal adenocarcinoma. (2013) (1)
- Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancer (2022) (1)
- Author response: Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma (2020) (1)
- The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research. (2020) (1)
- Immigration in science (2020) (1)
- Abstract B73: Pancreatic stellate cell heterogeneity in cancer (2016) (1)
- 20 Mouse Models of Pancreatic Exocrine Cancer (2010) (1)
- A Dynamic Contrast-Enhanced MRI Comparison of the Perfusion of Spontaneous and Transplanted Pancreatic Ductal Adenocarcinoma in Genetically Engineered Mice (2011) (0)
- Abstract 4042: Genomic and pharmaco-genomic profiling of pancreatic cancer using patient-derived organoids (2022) (0)
- Experimental approaches to ductal pancreatic cancer (2016) (0)
- Brief report Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways (2007) (0)
- Have you seen ? The RAS and YAP 1 dance , who is leading ? (2014) (0)
- Developmental and MAPK-responsive transcription factors drive distinct malignant subtypes and genetic dependencies in pancreatic cancer (2022) (0)
- Pancreatic stellate cells are immunosuppressive modulators in pancreatic ductal adenocarcinoma (2012) (0)
- Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies to self-antigens (2023) (0)
- Inhibition of mitochondrial metabolism by (-)-jerantinine A: synthesis and biological studies in triple-negative breast cancer cells. (2023) (0)
- Optogenetic stimulation of the brainstem dorsal motor nucleus ameliorates acute pancreatitis (2023) (0)
- CNprep: Copy number event detection (2020) (0)
- Decreased serum thrombospondin-1 levels in pancreatic ductal adenocarcinoma patients: an early indicator of disease or diabetes mellitus development? (2015) (0)
- Waging war against pancreatic cancer: an interview with David Tuveson (2017) (0)
- Loss of KRASG12D feedback regulation involving splicing factor SRSF1 accelerates pancreatic cancer (2021) (0)
- promotes mevalonate pathway dependency in pancreatic cancer. (2020) (0)
- Abstract IA5: Developing therapeutics in mice with ductal pancreatic cancer (2012) (0)
- Abstract B64: Using pancreatic organoids to infer therapeutic resistance and sensitivity (2016) (0)
- Organoids to study and stop pancreatic cancer (2016) (0)
- Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution (2020) (0)
- Pancreatic cancer foiled by a switch of tumour subtype (2018) (0)
- Accurate and robust inference of genetic ancestry from cancer-derived molecular data across genomic platforms (2022) (0)
- Using mouse and human pancreatic organoids to infer resistance to targeted therapy (2016) (0)
- Abstract B04: NRF2 regulates serine biosynthesis in pancreatic ductal adenocarcinoma (2016) (0)
- Anemia and Ineffective Erythropoiesis Caused by Somatic RAS Mutation. (2004) (0)
- Internally Controlled and Dynamic Optical Measures of Functional Tumor Biology (2022) (0)
- Generation and Characterisation of a $\textit{Pax8}$-CreER$^\text{T2}$ Transgenic Line and a $\textit{Slc22a6}$-CreER$^\text{T2}$ Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells (2016) (0)
- Corralling Pancreatic Cancer through Epigenetic Reprogramming (2018) (0)
- Abstract LB-374: The Hh inhibitor IPI-926 enhances tumor perfusion and nab-paclitaxel activity in a pancreatic xenograft model (2010) (0)
- Abstract 5128: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2019) (0)
- Abstract S04-01: Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalized patients: A case series (2020) (0)
- Cross-talk between IKK2 and Notch promotes pancreatic cancer progression in mice through Hes1 mediated PPAR gamma inhibitio (2011) (0)
- Abstract B22: Identifying protein interactors of oncogenic Kras in pancreatic cancer cells via proximity labelling (2020) (0)
- Cancer evention esearch ew loying Mouse Models of Pancreatic Cancer for Pr R moprevention Studies (2010) (0)
- Abstract B94: Fibroblast activation protein alpha-expressing stromal cells mediate immune suppression in the KPC mouse model of pancreatic ductal adenocarcinoma. (2012) (0)
- Abstract 1027: Development of orthotopically grafted organoid models to study pancreatic cancer progression (2016) (0)
- Pharmacotyping patients using pancreatic cancer organoids (2018) (0)
- Abstract IA11: Progress in pancreatic cancer modeling (2014) (0)
- p73 activates transcriptional signatures of basal lineage identity and ciliogenesis in pancreatic ductal adenocarcinoma (2023) (0)
- Abstract 798: Clonal analysis and clinical translation of pancreatic adenocarcinoma genomes. (2013) (0)
- In Vitro Analysis of Myeloid Proliferation Caused by Oncogenic Kras. (2004) (0)
- Abstract B25: Engrailed-1 promotes pancreatic cancer progression via antagonizing COMPASS activity (2019) (0)
- Abstract IA11: Pancreatic cancer biology and medicine (2016) (0)
- Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models (2020) (0)
- Abstract B72: Developing drug combinations to co-target pancreatic cancer and its supporting stroma (2015) (0)
- Abstract B063: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2020) (0)
- Pancreatic cancer medicine in mice. (2006) (0)
- Abstract IA13: Targeting redox dependencies in pancreatic cancer (2020) (0)
- Abstract 1572: FZD6 and RYK, non-canonical Wnt receptors in pancreatic cancer progression (2022) (0)
- The Early Detection of Pancreatic Cancer in the U.S. Military (2015) (0)
- Detecting and killing pancreatic cancer (2016) (0)
- Abstract PL03-03: K-RAS dependency in pancreatic cancer (2015) (0)
- Abstract IA-10: Overcoming the seven deadly hallmarks of pancreatic cancer (2020) (0)
- Abstract PR2: Therapeutic intervention targeting a Hedgehog-dependent barrier to drug delivery in pancreatic cancer (2010) (0)
- Decreased Serum Thrombospondin-1 Levels in Pancreatic Ductal Adenocarcinoma Patients: An Early Indicator of Cancer or Diabetes Development? (2015) (0)
- Abstract A23: A second site KrasG12D mutation that impairs PI3K binding rescues embryonic lethality, abrogates myeloproliferative disease, and delays lung tumorigenesis (2020) (0)
- Expressed during Pancreatic Cancer Progression Phenotypes in Pancreatic Cancer Cells and Is Increasingly The RON Receptor Tyrosine Kinase Mediates Oncogenic (2007) (0)
- NRF 2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer Graphical (0)
- 108 The Deubiquitinase USP9X Suppresses Pancreatic Ductal Adenocarcinoma (2012) (0)
- Abstract A007: Pancreatic cancer comprises co-existing transcriptional states regulated by distinct master regulator programs (2022) (0)
- Activated fibroblasts in cancer: Perspectives and challenges. (2023) (0)
- Background M402, a Novel Drug Candidate for Pancreatic Cancer: Efficacy in Animal Models and Initial Clinical Study Design (2014) (0)
- GEMMs and GEOs to characterize pancreatic cancer initiation and progression (2018) (0)
- Progress in pancreatic cancer modeling (2014) (0)
- Molecular Biology, Genomics, Proteomics, and Mouse Models of Human Cancer (2017) (0)
- GATA6 amplification is associated with improved survival of TP53-mutated pancreatic cancer (2023) (0)
- Abstract B55: Chemokine biased agonists regulate pancreatic cancer migration and metastasis through bioenergetic signaling (2015) (0)
- Expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1) in circulating tumor and invasive cells (CTICs) as a biomarker for drug resistance and disulfiram in pancreatic adenocarcinoma (PDAC). (2016) (0)
- Abstract 1223: Accurate inference of genetic ancestry from cancer-derived data (2022) (0)
- Su1907 Developing Drug Combinations to Co-Target Pancreatic Cancer and Its Supporting Stroma (2014) (0)
- Abstract 2805: Exome sequencing identifies frequent mutation of the SWI/SNF complex genePBRM1in renal carcinoma (2011) (0)
- PNAS Plus Significance Statements (2015) (0)
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution (2020) (0)
- Regulation of HDAC2-PDX1 by RNF125 defines pancreatic cancer development (2020) (0)
- Abstract 1895: Characterization of gemcitabine- and paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles as a treatment for pancreatic ductal adenocarcinoma using in vitro models (2022) (0)
- Abstract PR-011: Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates KrasG12D-mediated pancreatic cancer initiation (2021) (0)
- Abstract IA13: How much gemcitabine reaches the target… and does it matter? (2012) (0)
- Organoid models to interrogate GPCR regulation of pancreatic tumorigenesis (2017) (0)
- Abstract PO-002: Detection of chemotherapy-resistant pancreatic cancer using a glycan Biomarker (2020) (0)
- Abstract A27: Exploring the role of glycosylation in pancreatic disease (2018) (0)
- Abstract 2328: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2020) (0)
- Genetically Engineered Mice Harboring RAS Mutations as Models of Human Cancer: in Medias RAS (2006) (0)
- Abstract 6081: The transcription factor SPDEF promotes the survival of mucinous pancreatic ductal adenocarcinoma of the classical subtype (2022) (0)
- Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma (2020) (0)
- A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of mouse tubular epithelial cells (2014) (0)
- Molecular Oncology: Pancreatic cancer (2013) (0)
- Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. (2023) (0)
- Abstract LB-43: M402, a novel heparin sulphate mimetic, synergizes with gemcitabine to improve survival and reduce metastasis and epithelial-to-mesenchymal transition (EMT) in a genetically engineered mouse model for pancreatic cancer (2010) (0)
- Running title: PanIN neuroendocrine cells promote tumorigenesis Keywords: Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Intraepithelial Neoplasia (PanIN); Tumor Microenvironment; Sensory Nerves and Axons; Substance P (SP); Neurokinin 1 Receptor (NK1-R); Chromogranin A (CgA); Endocrine and Neur (2017) (0)
- Talk from David Tuveson at the Cold Spring Harbor Laboratory In-House Symposium (2012) (2012) (0)
- Abstract PR04: Nrf2 promotes mRNA translation in pancreatic cancer (2016) (0)
- Galectin-4 driven immunosuppression in pancreatic ductal adenocarcinoma (2021) (0)
- Recurrent noncoding regulatory mutations in pancreatic ductal 1 adenocarcinoma 2 3 4 5 6 7 (2017) (0)
- Abstract C084: Oncogenic KRAS signaling drives the activation of tissue-resident fibroblasts and is required to maintain CAF heterogeneity in pancreatic cancer (2022) (0)
- Abstract 2393: PDAC cells release BAG3 that activates a paracrine loop with stromal macrophages (2015) (0)
- Living biobank of endoscopic ultrasound guided fine needle biopsy-derived PDAC organoids: A study of two contrasting populations (2018) (0)
- Abstract B02: Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy (2019) (0)
- Abstract SY08-01: Large-scale screens for cancer genes in the mouse (2012) (0)
- Abstract 1819: Profiling of extracellular matrix proteins in pancreatic ductal adenocarcinoma progression and metastasis (2015) (0)
- Correction: Genetic Ancestry Inference from Cancer-Derived Molecular Data across Genomic and Transcriptomic Platforms. (2023) (0)
- Abstract A04: Identification of novel pancreatic cancer-specific biomarkers with organoid models (2016) (0)
- 194 Pancreatic ductal organoids as a new platform for drug discovery (2014) (0)
- Feasibility of implantable microdosing devices to perform in vivo pharmacotyping in pancreatic cancer. (2023) (0)
- The axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC (2023) (0)
- Abstract 1179: Global increase in ultraconserved non-coding RNA expression in pancreatic adenocarcinoma (2011) (0)
- Abstract IA11: T cell exclusion in pancreatic ductal adenocarcinoma: The FAP+ cancer-associated fibroblast and CXCL12 (2015) (0)
- Abstract B33: Inhibition of stromal-derived CTGF sensitizes murine pancreatic adenocarcinoma to gemcitabine treatment. (2012) (0)
- Multiparameter modalities for the study of patients in the setting of individualized medicine (2018) (0)
- Abstract A45: Understanding the roles of extracellular matrix proteins in pancreatic ductal adenocarcinoma progression and metastasis (2015) (0)
- Abstract A06: Identification of tumor-specific antibodies using phage display selections on pancreatic ductal organoids (2016) (0)
- Pancreatic cancer SLUGged (2020) (0)
- Abstract 3771: Capecitabine pharmacokinetics and efficacy in spontaneous tumors occurring in a genetically engineered mouse model (GEMM) of pancreatic cancer (2012) (0)
- LC-MS/MS analysis of gemcitabine and its metabolites in primary murine pancreatic tumors and liver metastases (2015) (0)
- In vivo imaging and targeted siRNA delivery using superparamagnetic nanoparticles in pancreatic ductal adenocarcinoma (2013) (0)
- Modeling pancreatic cancer biology and medicine (2014) (0)
- Abstract LB-011: Patient-derived organoids may facilitate precision medicine in pancreatic cancer: Demonstrating feasibility in the context of a multi-center clinical trial (2020) (0)
- Organoid Personalized Therapeutics and the Pancreatic Adenocarcinoma Signature Stratification for treatment (PASS) – 01 trial (2020) (0)
- Abstract B43: The utilization of extracellular proteins as nutrients is suppressed by mTORC1 (2016) (0)
- 65 Pancreatic Cancer Therapies (2012) (0)
- Treatment of gastrointestinal stroma-tumors (2001) (0)
- Brief Definitive Report (0)
- Abstract C037: Polyethnic-1000: A New York-based initiative to advance cancer genomics through recruitment of diverse racial & ethnic populations (2023) (0)
- Abstract 5446: The activity and pharmacokinetics of capecitabine in a mouse model (K8484) of pancreatic adenocarcinoma (2011) (0)
- Engrailed-1 Promotes Pancreatic Cancer Metastasis (2023) (0)
This paper list is powered by the following services:
Other Resources About David Tuveson
What Schools Are Affiliated With David Tuveson?
David Tuveson is affiliated with the following schools:
